Corvus Pharmaceuticals Reports Positive Soquelitinib Data, Stock Up 140%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Should l Buy CRVS?
Source: Benzinga
- Clinical Trial Results: Corvus Pharmaceuticals reported that in cohort 4 of its Phase 1 trial, soquelitinib achieved a mean EASI score reduction of 72% over 8 weeks, significantly outperforming the placebo group's 40%, indicating strong efficacy in treating moderate-to-severe atopic dermatitis.
- Patient Background Analysis: Among all four cohorts, 35% of patients had prior systemic therapy, with 50% in cohort 4, highlighting the potential value of soquelitinib in patients who have failed previous treatments.
- Biomarker Data: Patients in cohort 4 exhibited significant reductions in serum IL-4 cytokine levels, maintaining lower levels up to day 86 post-treatment, demonstrating soquelitinib's sustained efficacy and good safety profile, with no new safety signals reported.
- Future Trial Plans: Corvus is set to initiate a Phase 2 clinical trial of soquelitinib for atopic dermatitis in Q1 2026, aiming to enroll approximately 200 patients to further validate its efficacy and safety.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRVS
Wall Street analysts forecast CRVS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.760
Low
11.00
Averages
13.33
High
16.00
Current: 18.760
Low
11.00
Averages
13.33
High
16.00
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Corvus Pharmaceuticals Put Selling
- Options Selling Risk: Selling puts on Corvus Pharmaceuticals does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, which only benefits them if the stock declines by 62.9% to trigger the $8 strike price.
- Yield Analysis: The only upside for the put seller comes from the premium collected, yielding an annualized return of 10.2%, but this must be weighed against potential market risks and stock price volatility.
- Volatility Assessment: Corvus Pharmaceuticals has a trailing twelve-month volatility of 122%, based on the last 250 trading days, indicating significant price fluctuations and a relatively high risk for selling options.
- Market Price Comparison: With the current stock price at $21.47, selling puts at an $8 strike could lead to losses under adverse market conditions, necessitating careful evaluation of the risk-reward balance by investors.
See More
Momentum Is Beginning for These 3 Fast-Growing Stocks in 2026
S&P 500 Performance: The S&P 500 has seen a modest rise of just over 1% in early 2026, despite some individual companies performing exceptionally well, particularly in the biotech sector.
Corvus Pharmaceuticals: Corvus Pharmaceuticals has experienced significant stock growth, driven by positive trial data for its drug candidate, which showed a 72% reduction in eczema severity, and plans for a Phase 2 trial.
New Era Energy & Digital: New Era Energy has reported over 114% stock growth year-to-date, bolstered by a key partnership aimed at expanding its data center capacity, indicating a strategic pivot towards high-demand sectors.
USA Rare Earth: USA Rare Earth is focusing on addressing supply chain concerns for rare earth minerals, supported by a $1.6 billion investment from the federal government, while also aiming to provide domestic alternatives to meet increasing demand.
See More
Corvus Pharmaceuticals (CRVS) Stock Soars 211.8% to New All-Time High
- Clinical Trial Success: Corvus Pharmaceuticals' drug candidate demonstrated a 72% reduction in eczema severity in the first phase trial, significantly outperforming the 40% reduction seen in the placebo group, indicating its potential for treating moderate to severe eczema patients.
- Stock Surge: Last week, Corvus Pharmaceuticals' stock soared by 211.8%, reaching an all-time high of $26.95 on Friday, although it closed down 1.65% at $25.10, reflecting strong market enthusiasm for its clinical results.
- Follow-Up Trial Plans: The company plans to initiate a Phase 2 trial in Q1 2026, targeting 200 patients with moderate-to-severe atopic dermatitis, further validating the efficacy of soquelitinib and demonstrating its ongoing market development potential.
- Trial Design Details: The Phase 2 trial will consist of four cohorts of 50 patients each, testing different doses of soquelitinib over a 12-week period with a 30-day follow-up, aimed at providing robust clinical data to support future treatment options.
See More
Corvus Pharmaceuticals Upsizes Stock Offering to $175 Million for R&D and Working Capital
- Stock Offering Size: Corvus Pharmaceuticals has increased its public stock offering from $150 million to $175 million, planning to issue 7.9 million shares at a price of $22.15 per share, expected to close on January 23, 2026, enhancing liquidity for future growth initiatives.
- Use of R&D Funds: The net proceeds from this offering will be allocated to meet working capital needs, including capital expenditures and R&D costs for Phase 3 trials of T-cell lymphoma and Phase 2 trials for atopic dermatitis, hidradenitis suppurativa, and asthma, underscoring the company's commitment to drug development.
- Positive Clinical Trial Results: Corvus announced favorable safety and efficacy results from cohort 4 of its placebo-controlled trial for atopic dermatitis, with all patients completing the 56-day treatment, boosting confidence that soquelitinib could emerge as a leading oral therapy in the market.
- Optimistic Market Sentiment: Retail sentiment on Stocktwits around Corvus is bullish, with extremely high message volume, as investors believe the stock could rise significantly post-offering, reflecting strong confidence in the company's growth prospects.
See More
Corvus Pharmaceuticals Prices $175M Upsized Public Offering to Fund Clinical Trials
- Offering Size: Corvus Pharmaceuticals has priced an upsized public offering of 7.9 million shares at $22.15 each, with gross proceeds expected to be approximately $175 million, reflecting strong market confidence in the company's growth prospects.
- Use of Proceeds: The net proceeds from this offering will be allocated for working capital and general corporate purposes, including capital expenditures and R&D, particularly for its Phase 3 T-cell lymphoma and Phase 2 atopic dermatitis clinical trials, aiming to accelerate product development.
- Underwriters' Option: The underwriters have a 30-day option to purchase an additional ~1.18 million shares, providing the company with potential additional financing flexibility and enhancing its capital structure stability.
- Expected Closing Date: The offering is anticipated to close on or about January 23, 2026, marking a proactive capital market strategy that supports future clinical trials and marketing efforts.
See More
Corvus Pharmaceuticals Prices Upsized Offering of 7.9 Million Shares at $22.15, Raising $175 Million
- Upsized Offering: Corvus Pharmaceuticals announced the pricing of 7,900,677 shares at $22.15 each, raising approximately $175 million, indicating strong market demand for its clinical-stage biopharmaceutical products.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 1,185,101 shares, enhancing financial flexibility and potentially providing more funding for future R&D and marketing efforts.
- Clear Use of Proceeds: The net proceeds will be allocated for working capital and general corporate purposes, including capital expenditures and R&D for multiple clinical trials, reflecting the company's proactive growth strategy.
- Strong Underwriting Team: With Jefferies and Goldman Sachs as lead underwriters, confidence in Corvus is evident, and the offering is expected to close on January 23, 2026, further solidifying its position in the biopharmaceutical industry.
See More
Analysis of Corvus Pharmaceuticals Put Selling
- Options Selling Risk: Selling puts on Corvus Pharmaceuticals does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, which only benefits them if the stock declines by 62.9% to trigger the $8 strike price.
- Yield Analysis: The only upside for the put seller comes from the premium collected, yielding an annualized return of 10.2%, but this must be weighed against potential market risks and stock price volatility.
- Volatility Assessment: Corvus Pharmaceuticals has a trailing twelve-month volatility of 122%, based on the last 250 trading days, indicating significant price fluctuations and a relatively high risk for selling options.
- Market Price Comparison: With the current stock price at $21.47, selling puts at an $8 strike could lead to losses under adverse market conditions, necessitating careful evaluation of the risk-reward balance by investors.
See More
Momentum Is Beginning for These 3 Fast-Growing Stocks in 2026
S&P 500 Performance: The S&P 500 has seen a modest rise of just over 1% in early 2026, despite some individual companies performing exceptionally well, particularly in the biotech sector.
Corvus Pharmaceuticals: Corvus Pharmaceuticals has experienced significant stock growth, driven by positive trial data for its drug candidate, which showed a 72% reduction in eczema severity, and plans for a Phase 2 trial.
New Era Energy & Digital: New Era Energy has reported over 114% stock growth year-to-date, bolstered by a key partnership aimed at expanding its data center capacity, indicating a strategic pivot towards high-demand sectors.
USA Rare Earth: USA Rare Earth is focusing on addressing supply chain concerns for rare earth minerals, supported by a $1.6 billion investment from the federal government, while also aiming to provide domestic alternatives to meet increasing demand.
See More
Corvus Pharmaceuticals (CRVS) Stock Soars 211.8% to New All-Time High
- Clinical Trial Success: Corvus Pharmaceuticals' drug candidate demonstrated a 72% reduction in eczema severity in the first phase trial, significantly outperforming the 40% reduction seen in the placebo group, indicating its potential for treating moderate to severe eczema patients.
- Stock Surge: Last week, Corvus Pharmaceuticals' stock soared by 211.8%, reaching an all-time high of $26.95 on Friday, although it closed down 1.65% at $25.10, reflecting strong market enthusiasm for its clinical results.
- Follow-Up Trial Plans: The company plans to initiate a Phase 2 trial in Q1 2026, targeting 200 patients with moderate-to-severe atopic dermatitis, further validating the efficacy of soquelitinib and demonstrating its ongoing market development potential.
- Trial Design Details: The Phase 2 trial will consist of four cohorts of 50 patients each, testing different doses of soquelitinib over a 12-week period with a 30-day follow-up, aimed at providing robust clinical data to support future treatment options.
See More
Corvus Pharmaceuticals Upsizes Stock Offering to $175 Million for R&D and Working Capital
- Stock Offering Size: Corvus Pharmaceuticals has increased its public stock offering from $150 million to $175 million, planning to issue 7.9 million shares at a price of $22.15 per share, expected to close on January 23, 2026, enhancing liquidity for future growth initiatives.
- Use of R&D Funds: The net proceeds from this offering will be allocated to meet working capital needs, including capital expenditures and R&D costs for Phase 3 trials of T-cell lymphoma and Phase 2 trials for atopic dermatitis, hidradenitis suppurativa, and asthma, underscoring the company's commitment to drug development.
- Positive Clinical Trial Results: Corvus announced favorable safety and efficacy results from cohort 4 of its placebo-controlled trial for atopic dermatitis, with all patients completing the 56-day treatment, boosting confidence that soquelitinib could emerge as a leading oral therapy in the market.
- Optimistic Market Sentiment: Retail sentiment on Stocktwits around Corvus is bullish, with extremely high message volume, as investors believe the stock could rise significantly post-offering, reflecting strong confidence in the company's growth prospects.
See More
Corvus Pharmaceuticals Prices $175M Upsized Public Offering to Fund Clinical Trials
- Offering Size: Corvus Pharmaceuticals has priced an upsized public offering of 7.9 million shares at $22.15 each, with gross proceeds expected to be approximately $175 million, reflecting strong market confidence in the company's growth prospects.
- Use of Proceeds: The net proceeds from this offering will be allocated for working capital and general corporate purposes, including capital expenditures and R&D, particularly for its Phase 3 T-cell lymphoma and Phase 2 atopic dermatitis clinical trials, aiming to accelerate product development.
- Underwriters' Option: The underwriters have a 30-day option to purchase an additional ~1.18 million shares, providing the company with potential additional financing flexibility and enhancing its capital structure stability.
- Expected Closing Date: The offering is anticipated to close on or about January 23, 2026, marking a proactive capital market strategy that supports future clinical trials and marketing efforts.
See More
Corvus Pharmaceuticals Prices Upsized Offering of 7.9 Million Shares at $22.15, Raising $175 Million
- Upsized Offering: Corvus Pharmaceuticals announced the pricing of 7,900,677 shares at $22.15 each, raising approximately $175 million, indicating strong market demand for its clinical-stage biopharmaceutical products.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 1,185,101 shares, enhancing financial flexibility and potentially providing more funding for future R&D and marketing efforts.
- Clear Use of Proceeds: The net proceeds will be allocated for working capital and general corporate purposes, including capital expenditures and R&D for multiple clinical trials, reflecting the company's proactive growth strategy.
- Strong Underwriting Team: With Jefferies and Goldman Sachs as lead underwriters, confidence in Corvus is evident, and the offering is expected to close on January 23, 2026, further solidifying its position in the biopharmaceutical industry.
See More
